1529 Treffer:
181.
Decision for or against Anti-PD-1 Treatment In Adjuvant Setting of Patients across Europe with Resected Stage IIB/IIC Melanoma
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-05-09
182.
A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresect
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-05-09
183.
A prospective, observational, multicenter clinical performance study to evaluate IOpener®-melanoma test for predicting response to combination or mono immunotherapy in stage III or IV cutaneous melanoma patients
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-05-09
184.
Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-05-09
185.
A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER® Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-05-09
186.
Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumo
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-05-09
187.
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-05-09
188.
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-05-09
189.
The CAROLYN Trial: Lisocabtagene Maraleucelas First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Myelodysplastisches Syndrom (MDS)
Datum: 2026-05-09
190.
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematolo
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Myelodysplastisches Syndrom (MDS)
Datum: 2026-05-09